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ent aryl aldehydes, which in turn treated with guanidine nitrate, yielded 4-(substituted phenyl)-6-
(substituted phenyl)-2-pyrimidinamines 2a–h. Novel pyrimidine–quinoline clubbed molecules 3a–
h have been prepared by reaction of 2a–h with 4-chloro-2,6-dimethylquinoline. All the compounds
were characterized by elemental analysis and spectral studies. The newly synthesized compounds
were evaluated for their antibacterial and antifungal activities.
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Heterocycles are abundant in nature and are of great signiﬁ-
cance to life because their structural subunits exist in many
natural products such as vitamins, hormones, antibiotics and
alkaloids, as well as in pharmaceuticals, herbicides, dyes, and
many more compounds (Katritzky and Pozharskii, 2000; Noga
et al., 1986; Craig, 1991; Kodama et al., 2003; Padwa and Bur,
2004). Hence, they have attracted considerable attention in the.in (A.A. Patel).
ity.
lsevierdesign of biologically active molecules (Mori et al., 2003;
Masui et al., 2004; Nagaraj and Sanjeeva Reddy, 2008).
Several pyrimidine derivatives possess a broad spectrum of
biological effectiveness such as antimicrobial (Nagaraj and
Sanjeeva Reddy, 2008; Anunakumar et al., 2006), calcium
channel blockers (Atwal et al., 1990, 1991, 1992; Rovnyak
et al., 1995), antitubercular (Nimavat et al., 2003), anticancer
(Nimavat et al., 2003), antibacterial (Vashi and Naik, 2005;
Vyas et al., 2008; Bharucha and Naik, 1999), and anti-inﬂam-
matory (Amir and Javed, 2008). Quinoline derivatives are also
drugs of therapeutic importance showing a wide spectrum of
biological activities and some 4-substituted quinoline deriva-
tives have been found to possess enhanced antibacterial activ-
ity (Naik and Mehta, 1989, 1987, Desai et al., 1993; Mehta
et al., 1993). If pyrimidine and quinoline moieties clubbed into
one molecule, the resultant molecule may enhance the pharma-
ceutical activity up to some extent. Hence, it was thought inter-
esting to explore the study of such molecules. Thus, the present
paper describes the synthesis of N4-[4-6-diaryl substituted
CH3
CH3
N CH3
CH3
OH
POCl3
N CH3
CH3
Cl
NH2
+ CH3COCH2COOC2H5
kept  in  a  desiccator
for  24  hours
with the drop  of 
conc.HCl
N
C CH3
CH2
C
O
H5C2O Cyclisation 
with
PPA
Scheme 1 Synthesis of 4-chloro-2,6-dimethylquinoline.
204 A.A. Patel, A.G. Mehtaphenyl-2-pyrimidinyl]-2,6-dimethyl-4-quinolinamine derived
from 2-amino-4,6-diarylsubstituted pyrimidine derivatives
and 4-chloro-2,6-dimethylquinoline (Bulidon and Pavan,
1991; Joly, 1971; Bangdiwala and Desai, 1953). The research
work is scanned in Schemes 1 and 2.
2. Experimental
2.1. Materials
All reagents were obtained from commercial sources. Solvents
were dried and puriﬁed with known conventional methods.
2.2. Analytical methods
All melting points were taken in open capillary tubes and were
uncorrected. Thin layer chromatography was performed on
precoated TLC plates with silica gel (Merck GF254) and
detection was done by UV lamp (254 nm). The IR spectra were
obtained on a Perkin–Elmer BX series FT-IR-5000 spectro-
photometer using KBr pellets. The 1H NMR and 13C NMR
spectra in DMSO-d6 and CDCl3 were recorded on Varian
Gemini 400 MHz spectrometer and chemical shifts were re-
ported as parts per million (d ppm) downﬁeld using TMS as
an internal standard. LC–MS of the selected sample has been
carried out on LC-MSD Trap-SL 01046 instrument.
2.3. Preparation of 2-amino-4,6-diaryl substituted pyrimidines
(2a–h)
A mixture of substituted chalcones (0.01 mol) 1a–h and guani-
dine nitrate (0.01 mol) was dissolved in ethanol (30 ml). Aque-
ous sodium hydroxide (40%, 1 ml) was added and the reaction
mixture was reﬂuxed. Further installments of sodium hydrox-
ide (4 · 1 ml) were added for 2 h to the reﬂuxing solution.Reﬂuxing was continued (10–12 h) and the completion of the
reaction was monitored by TLC. The resultant mixture was
cooled at room temperature, diluted with water (3 · 100 ml)
and neutralized with cold dilute HCl (10%). The product thus
separated was ﬁltered out, washed with water dried and crys-
tallized from ethanol.
Following the same procedure all the compounds of this
series were prepared.
2.3.1. 4-(2,4-Dichloro-5-ﬂuorophenyl)-6-(40-ﬂuorophenyl)-2-
pyrimidinamine (2a)
Yield 70%; mp: 153 C; FT-IR [m, cm1, KBr]: 3420 (–NH2),
1257 (C–N), 1109 (C–F), 820 (C–Cl). 1H NMR [400 MHz, d,
ppm, CDCl3]: 5.39 (2H, s, NH2), 6.95–7.86 (7H, m, Ar-H).
LC–MS: m/z 353 (M+). Anal. Calcd for C16H9N3Cl2F2
(352.16): C, 54.57; H, 2.58; N, 11.93. Found: C, 54.50; H,
2.51; N, 11.87.
2.3.2. 4-(4-Methoxyphenyl)-6-(40-ﬂuorophenyl)-2-
pyrimidinamine (2b)
Yield 68%; mp: 149 C; FT-IR [m, cm1, KBr]: 3433 (–NH2),
1291 (C–N), 2826 (OCH3), 1182 (C–F).
1H NMR [400 MHz,
d, ppm, CDCl3]: 5.43 (2H, s, NH2), 3.75 (3H, s, –OCH3),
6.80–7.98 (9H, m, Ar-H). Anal. Calcd for C17H14FN3O
(295.31): C, 69.10; H, 4.78; N, 14.23. Found: C, 69.07; H,
4.69; N, 14.16.
2.3.3. 4-(4-Methylphenyl)-6-(40-ﬂuorophenyl)-2-
pyrimidinamine (2c)
Yield 65%; mp: 139 C; FT-IR [m, cm1, KBr]: 3449 (–NH2),
1340 (C–N), 2919 (CH3), 1161 (C–F).
1H NMR [400 MHz,
d, ppm, CDCl3]: 5.35 (2H, s, NH2), 2.39 (3H, s, –CH3),
6.94–7.81 (9H, m, Ar-H). Anal. Calcd for C17H14N3F
(279.31): C, 73.10; H, 5.05; N, 15.04. Found C, 73.02; H,
4.95; N, 14.98.
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Where 
(a) R2=R4=Cl; R'4=R5=F; R'3=H  (e) R2=R5=R'4=H; R4=CH3; R'3=Br 
(b) R2=R5=R'3=H; R4=OCH3; R'4=F (f) R2=R5=R'4=H; R4=OCH3; R'3=Br 
(c) R2=R5=R'3=H; R4=CH3; R'4=F  (g) R2=R5=R'4=H; R4=Cl; R'3=NO2
(d) R2=R5=R'4=H; R4=Cl; R'3=Br  (h) R2=R5=R'4=H; R4=OCH3; R'3=NO2
Scheme 2 Synthesis route of compounds 3a–h.
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pyrimidinamine (2d)
Yield 69%; mp: 168 C; FT-IR [m, cm1, KBr]: 3460 (–NH2),
1311 (C–N), 1019 (C–Br), 803 (C–Cl). 1H NMR [400 MHz,
d, ppm, CDCl3]: 5.47 (2H, s, NH2), 7.01–8.11 (9H, m, Ar-
H). Anal. Calcd for C16H11N3ClBr (360.63): C, 53.29; H,
3.07; N, 11.65. Found C, 53.20; H, 3.01; N, 11.60.
2.3.5. 4-(4-Methylphenyl)-6-(30-bromophenyl)-2-
pyrimidinamine (2e)
Yield 61%; mp: 159 C; FT-IR [m, cm1, KBr]: 3452 (–NH2),
1296 (C–N), 2913 (CH3), 1074 (C–Br).
1H NMR [400 MHz,
d, ppm, CDCl3]: 5.39 (2H, s, NH2), 2.48 (3H, s, –CH3),
6.94–7.91 (9H, m, Ar-H). Anal. Calcd for C17H14N3Br
(340.21): C, 60.02; H, 4.15; N, 12.35. Found C, 59.97; H,
4.09; N, 12.26.
2.3.6. 4-(4-Methoxyphenyl)-6-(30-bromophenyl)-2-
pyrimidinamine (2f)
Yield 66%; mp: 171 C; FT-IR [m, cm1, KBr]: 3432 (–NH2),
1287 (C–N), 2816 (OCH3), 1069 (C–Br).
1H NMR[400 MHz, d, ppm, CDCl3]: 5.37 (2H, s, NH2), 3.77 (3H, s,
–OCH3), 6.97–8.19 (9H, m, Ar-H). Anal. Calcd for
C17H14ON3Br (356.21): C, 57.32; H, 3.96; N, 11.80. Found
C, 57.27; H, 3.89; N, 11.75.
2.3.7. 4-(4-Chlorophenyl)-6-(30-nitrophenyl)-2-pyrimidinamine
(2g)
Yield 60%; mp: 191 C; FT-IR [m, cm1, KBr]: 3428 (–NH2),
1517 (NO2), 1277 (C–N), 783 (C–Cl).
1H NMR [400 MHz, d,
ppm, CDCl3]: 5.48 (2H, s, NH2), 7.18–8.39 (9H, m, Ar-H).
13C NMR [400 MHz, d, ppm, CDCl3]: 163.6 (C–NH2), 134.3
(C–Cl), 148.4 (C–NO2), 163.6–165.2 (C‚N), 162.0–163.6
(C–N), 101.3–129.3 (aromatic carbons). LC–MS: m/z 327
(M+). Anal. Calcd for C16H11O2N4Cl (326.7): C, 58.82; H,
3.39; N, 17.15. Found: C, 58.78; H, 3.30; N, 17.10.
2.3.8. 4-(4-Methoxyphenyl)-6-(30-nitrophenyl)-2-
pyrimidinamine (2h)
Yield 64%; mp: 161 C; FT-IR [m, cm1, KBr]: 3458 (–NH2),
2826 (OCH3), 1545 (NO2), 1250 (C–N).
1H NMR [400 MHz,
d, ppm, CDCl3]: 5.44 (2H, s, NH2), 3.69 (3H, s, –OCH3),
206 A.A. Patel, A.G. Mehta7.09–8.33 (9H, m, Ar-H). Anal. Calcd for C17H14O3N4
(322.31): C, 63.35; H, 4.38; N, 17.38. Found: C, 63.26; H,
4.25; N, 17.29.
2.4. Preparation of 4-chloro-2,6-dimethylquinoline (Scheme 1)
2.4.1. Ethyl-b-4-chloroanilinocrotonate
A mixture of p-toluidine (0.05 mol) and acetoacetic ester
(0.05 mol) with a trace of concentrated hydrochloric acid
was kept in a desiccator for 24 h. The residue was cyclized
by PPA.
2.4.2. Polyphosphoric acid (PPA)
Polyphosphoric acid was prepared by dissolving phosphorus
pentoxide (40.0 g) into orthophosphoric acid (24 ml;
d= 1.75). The mixture was heated at 95–100 C for half an
hour; the scum was removed and clear solution thus obtained
was used for the cyclization step.
2.4.3. 2,6-Dimethyl-4-quinolinol
The crude crotonate was mixed with freshly prepared PPA at
room temperature, stirred well for some time and then the tem-
perature was raised to 100 C effervescences and was kept in
desiccators for 24 h. Next day, the temperature was slowly
raised and lowered by 10 C until it reached 140 C over
1 hr. This treatment helps in getting clean product in high
yield. The reaction mass was cooled and decomposed with
crushed ice and neutralized with ammonium hydroxide on
the acidic side. The product was ﬁltered washed with water
dried and crystallized from alcohol, yield 78%, mp 321 C.
2.4.4. 4-Chloro-2,6-dimethylquinoline
2,6-Dimethyl-4-quinolinol (3.0 g) was reﬂuxed with phospho-
rus oxychloride (25.0 ml) for half an hour. After cooling to
room temperature, it was poured in ice and neutralized with
ammonium hydroxide on the acidic side, when a voluminous
mass of chloro compound separated. The product was washed
with water and crystallized from ethanol.
Yield 79%, mp 77–79 C. FT-IR [m, cm1, KBr]: 3052 (C–H
aromatic), 2970 (CH3), 820 (C–Cl).
1H NMR [400 MHz, d,
ppm, CDCl3]: 2.45 (3H, s, –CH3), 2.61 (3H, s, –CH3), 7.38–
8.17 (4H, m, Ar-H). Anal. Calcd for C11H10ClN (191.65): C,
68.93; H, 5.26; N, 7.31. Found: C, 68.87; H, 5.22; N, 7.25.
2.5. General procedure for the preparation of N4-[4-6-diaryl
substituted phenyl-2-pyrimidinyl]-2,6-dimethyl-4-quinolinamine
(3a–h)
To a mixture of 2-amino-4,6-diaryl substituted pyrimidines
(0.01 mol) 2a–h and 4-chloro-2,6-dimethylquinoline
(0.01 mol) in THF, anhydrous K2CO3 (0.11 mol) was added.
The reaction mixture was reﬂuxed. TLC [toluene–ethyl ace-
tate–acetone; 5:3:2] showed that reaction was completed after
8 h. The reaction mixture was poured in ice water and the pre-
cipitate was ﬁltered, washed with water, dried and crystallized
from ethanol.
2.5.1. N4-[4-(2,4-Dichloro-5-ﬂuorophenyl)-6-(40-
ﬂuorophenyl)-2-pyrimidinyl]-2,6-dimethyl-4-quinolinamine
(3a)
Yield 86%; mp: 207 C; FT-IR [m, cm1, KBr]: 3367 (N–H),
2972 (CH3), 1357 (C–N), 1118 (C–F), 822 (C–Cl).
1H NMR[400 MHz, d, ppm, DMSO-d6]: 6.84 (1H, s, –NH), 2.32 (3H,
s, –CH3), 2.42 (3H, s, –CH3), 6.99–7.93 (11H, m, Ar-H).
13C
NMR [400 MHz, d, ppm, DMSO-d6]: 148.3–169.7 (C–NH–
C), 115.4–129.2 (C–Cl), 161.4–162.9 (C–F), 20.0–21.7 (C–
CH3), in pyrimidine ring 165.2–169.7 (C‚N), 162.0–169.7
(C–N), in Quinoline ring 158.0 (C‚N), 147.2 (C–N) and
101.3–132.5 (aromatic carbons). LC–MS: m/z 508 (M+). Anal.
Calcd for C27H18Cl2F2N4 (507.36): C, 63.92; H, 3.58; N, 11.04.
Found: C, 63.87; H, 3.49; N, 10.8.
2.5.2. N4-[4-(4-Methoxyphenyl)-6-(40-ﬂuorophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3b)
Yield 88%; mp: 203 C; FT-IR [m, cm1, KBr]: 3349 (N–H),
2952 (CH3), 2839 (OCH3), 1349 (C–N), 1160 (C–F).
1H
NMR [400 MHz, d, ppm, DMSO-d6]: 6.86 (1H, s, –NH),
2.35 (3H, s, –CH3), 2.39 (3H, s, –CH3), 3.70 (3H, s, –OCH3),
7.05–7.92 (13H, m, Ar-H). Anal. Calcd for C28H23FN4O
(450.50): C, 74.65; H, 5.15; N, 12.44. Found: C, 74.60; H,
5.11; N, 12.39.
2.5.3. N4-[4-(4-Methylphenyl)-6-(40-ﬂuorophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3c)
Yield 84%; mp: 195 C; FT-IR [m, cm1, KBr]: 3329 (N–H),
2932 (CH3), 1351 (C–N), 1160 (C–F).
1H NMR [400 MHz,
d, ppm, DMSO-d6]: 6.87 (1H, s, –NH), 2.32 (3H, s, –CH3),
2.36 (3H, s, –CH3), 3.42 (3H, s, –CH3), 7.075–7.93 (13H, m,
Ar-H). Anal. Calcd for C28H23FN4 (434.50): C, 77.40; H,
5.34; N, 12.89. Found: C, 77.35; H, 5.28; N, 12.81.
2.5.4. N4-[4-(4-Chlorophenyl)-6-(30-bromophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3d)
Yield 85%; mp: 198 C; FT-IR [m, cm1, KBr]: 3369 (N–H),
2939 (CH3), 1337 (C–N), 1021 (C–Br), 811 (C–Cl).
1H NMR
[400 MHz, d, ppm, DMSO-d6]: 6.86 (1H, s, –NH), 2.33 (3H,
s, –CH3), 2.40 (3H, s, –CH3), 7.07–8.12 (13H, m, Ar-H). Anal.
Calcd for C27H20BrClN4 (515.83): C, 62.87; H, 3.91; N, 10.86.
Found: C, 62.82; H, 3.86; N, 10.80.
2.5.5. N4-[4-(4-Methylphenyl)-6-(30-bromophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3e)
Yield 85%; mp: 201 C; FT-IR [m, cm1, KBr]: 3394 (N–H),
2931 (CH3), 1329 (C–N), 1072 (C–Br).
1H NMR [400 MHz,
d, ppm, DMSO-d6]: 6.88 (1H, s, –NH), 2.32 (3H, s, –CH3),
2.36 (3H, s, –CH3), 2.40 (3H, s, –CH3), 7.08–8.12 (13H, m,
Ar-H). Anal. Calcd for C28H23BrN4 (495.41): C, 67.88; H,
4.68; N, 11.31. Found: C, 67.82; H, 4.61; N, 11.25.
2.5.6. N4-[4-(4-Methoxyphenyl)-6-(30-bromophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3f)
Yield 88%; mp: 196 C; FT-IR [m, cm1, KBr]: 3357 (N–H),
2971 (CH3), 2810 (OCH3), 1309 (C–N), 1062 (C–Br).
1H
NMR [400 MHz, d, ppm, DMSO-d6]: 6.85 (1H, s, –NH),
2.33 (3H, s, –CH3), 2.41 (3H, s, –CH3), 3.74 (3H, s, –OCH3),
7.05–8.14 (13H, m, Ar-H). Anal. Calcd for C28H23BrN4O
(511.41): C, 65.76; H, 4.53; N, 10.96. Found: C, 65.71; H,
4.43; N, 10.87.
2.5.7. N4-[4-(4-Chlorophenyl)-6-(30-nitrophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3g)
Yield 84%; mp: 199 C; FT-IR [m, cm1, KBr]: 3340 (N–H),
2963 (CH3), 1519 (NO2), 1397 (C–N).
1H NMR [400 MHz,
d, ppm, DMSO-d6]: 6.84 (1H, s, –NH), 2.31 (3H, s, –CH3),
Synthesis and characterization of some pyrimidine–quinoline clubbed molecules 2072.39 (3H, s, –CH3), 7.08–8.20 (13H, m, Ar-H).
13C NMR
[400 MHz, d, ppm, DMSO-d6]: 148.9–170.3 (C–NH–C),
134.4 (C–Cl), 148.5 (C–NO2), 20.2–21.8 (C–CH3), in pyrimi-
dine ring 165.5–169.8 (C‚N), 162.7–169.7 (C–N), in quinoline
ring 158.3 (C‚N), 147.5 (C–N) and 101.4–130.9 (aromatic
carbons). LC–MS: m/z 482 (M+). Anal. Calcd for
C27H20ClN5O2 (481.93); C, 67.29; H, 4.18; N, 14.53. Found:
C, 67.23; H, 4.12; N, 14.51.
2.5.8. N4-[4-(4-Methoxyphenyl)-6-(30-nitrophenyl)-2-
pyrimidinyl]-2,6-dimethyl-4-quinolinamine (3h)
Yield 85%; mp: 194 C; FT-IR [m, cm1, KBr]: 3352 (N–H),
2947 (CH3), 2843 (OCH3), 1528 (NO2), 1389 (C–N), 785
(C–Cl). 1H NMR [400 MHz, d, ppm, DMSO-d6]: 6.88 (1H,
s, –NH), 2.33 (3H, s, –CH3), 2.42 (3H, s, –CH3), 3.72 (3H, s,
–OCH3), 7.04–8.20 (13H, m, Ar-H). Anal. Calcd for
C28H23N5O3 (477.51): C, 70.43; H, 4.85; N, 14.67. Found: C,
70.36; H, 4.81; N, 14.60.3. Results and discussion
3.1. Chemistry
Chalcones 1a–h were prepared by the reported method and
were cyclized with guanidine nitrate to give 4-6-diarylsubstitut-
ed-2-pyrimidinamines 2a–h. The latter compounds further
reacted with 2,6-dimethyl-4-chloroquinoline to give the corres-
ponding compounds 3a–h.
Compounds 2a–h and 3a–h were conﬁrmed on the basis of
the elemental analysis and spectroscopic investigation. IR
spectrum of 2a–h revealed characteristic bands at 3460–Table 1 Biological activity of N4-[4-6-diaryl substituted phenyl-2-p
Zone of inhibitiona (mm) (activity index)std
Compd. Antibacterial activity
Gram-positive Gram-n
S. aureus S. pyogenes E. coli
3a 19(0.95)
(0.86)
18(0.90)
(0.85)
20(0.86)
(0.71)
3b 18(0.90)
(0.81)
17(0.85)
(0.80)
19(0.82)
(0.67)
3c 15(0.75)
(0.68)
13(0.65)
(0.61)
14(0.60)
(0.50)
3d 18(0.90)
(0.81)
16(0.80)
(0.76)
19(0.82)
(0.67)
3e 14(0.70)
(0.63)
12(0.60)
(0.57)
17(0.73)
(0.60)
3f 19(0.95)
(0.86)
18(0.90)
(0.85)
21(0.91)
(0.75)
3g 15(0.75)
(0.68)
14(0.70)
(0.66)
15(0.65)
(0.53)
3h 13(0.65)
(0.59)
13(0.65)
(0.61)
16(0.69)
(0.57)
Std. 1 20 20 23
Std. 2 22 21 28
(Activity index) = Inhibition zone of the sample/Inhibition zone of the s
For antibacterial activity: Std. 1 = chloramphenicol and Std. 2 = ciproﬂ
For antifungal activity: Std. 1 = griseofulvin and Std. 2 = nystatin.
a Average zone of inhibition in mm.3300 cm1 (–NH2), 1340–1250 cm
1 (C–N) and conﬁrmatory
by 1H NMR signal at d 5.4 (2H, s, –NH2). Further, IR spectro-
scopic investigation of 3a–h revealed bands at 3375–3329 cm1
(N–H) and 1608 (C‚N) while additional peak appears due to
substitution in the aromatic ring showing absorption band at
2953 (–CH3), 2810 (–OCH3), 1528 (–NO2), 1100 (C–
F), 1050 (C–Br), 810 (C–Cl). 1H NMR signal at d 6.8
(1H, s, –NH) and additional signal appear due to substitution
in aromatic ring showing common signals at d 2.3 (3H, s,
–CH3), d 3.7 (3H, s, –OCH3) and d (6.9–8.0, m, aromatic
protons).
The ﬁnal structure of all compounds was conﬁrmed by 13C
NMR and LC–MS data of selected samples. The LC–MS of
samples 2a, 2g, 3a and 3g give the molecular ion peak (m/z)
at 353, 327, 508 and 482, respectively. These values correspond
to their molecular weight.
3.2. Biological activity
3.2.1. Antibacterial activity
Antibacterial activities of all the compounds were studied
against Gram-positive bacteria [Staphylococcus aureus
(MTCC96), Streptococcus pyogenes (MTCC442)] and
Gram-negative bacteria [Escherichia coli (MTCC443), Pseu-
domonas aeruginosa (MTCC424)] at a concentration of
100 lg/ml by agar cup plate method. The test compounds were
dissolved in DMF at a concentration of 100 lg/mL using
Chloramphenicol and Ciproﬂoxacin as standard for compari-
son control experiment was carried out. The area of inhibition
of zone measured in millimeter. An examination of the data re-
veals that all compounds showed antibacterial activity. Results
are presented in Table 1.yrimidinyl]-2,6-dimethyl-4-quinolinamines (3a–h).
Antifungal activity
egative C. albicans A. niger
P. aeruginosa
18(0.94)
(0.69)
20(0.90)
(0.74)
23(0.92)
(0.79)
16(0.84)
(0.61)
19(0.86)
(0.70)
22(0.88)
(0.75)
13(0.68)
(0.50)
17(0.77)
(0.62)
19(0.76)
(0.65)
17(0.89)
(0.65)
21(0.95)
(0.77)
21(0.84)
(0.72)
13(0.68)
(0.50)
17(0.77)
(0.62)
20(0.80)
(0.68)
16(0.84)
(0.61)
20(0.90)
(0.74)
22(0.88)
(0.75)
15(0.78)
(0.57)
18(0.81)
(0.66)
19(0.76)
(0.65)
12(0.63)
(0.46)
21(0.95)
(0.77)
20(0.80)
(0.68)
19 22 25
26 27 29
tandard.
oxacin.
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The synthesized compounds were also screened for their anti-
fungal activity against Candida albicans (MTCC227), Asper-
gillus niger (MTCC282) using the agar cup plate diffusion
method by dissolving in DMF at a concentration of 100 lg/
mL. The zone of inhibition was measured after 7 days at
20 C and it was compared with the standard drugs Griseoful-
vin and Nystatin as shown in Table 1.
4. Conclusion
The clubbing of 2-amino-4,6-diaryl substituted pyrimidine
derivatives and 4-chloro-2,6-dimethylquinoline has been done
successfully into one molecule. The antimicrobial activity of
N4-[4-6-diaryl substituted phenyl-2-pyrimidinyl]-2,6-di-
methyl-4-quinolinamines 3a–h was carried out against some
strain bacteria. The results show that the synthesized com-
pounds were toxic against the bacteria. The comparison of
the antibacterial and antifungal activities of these compounds
with the standard drugs shows that the presence of methoxy
and halogen (–Cl, –Br, and –F) groups in the phenyl ring in-
creases the antimicrobial activity. Their potency has been
found to be lower than that of the standard drugs, but their
acute toxicity is signiﬁcantly lower.References
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